Background Incomplete revascularisation is common after percutaneous coronary
intervention and is associated with increased mortality and adverse cardiovascular events …

Background—Angina often persists or returns in populations following percutaneous
coronary intervention (PCI). We hypothesized that ranolazine would be effective in reducing …

Background Ranolazine, a piperazine derivative with anti‐ischemic effects, reduces the
frequency of angina and improves exercise performance in patients with chronic angina …

ContextRanolazine is a novel antianginal agent that reduces ischemia in patients with
chronic angina but has not been studied in patients with acute coronary syndromes (ACS) …

Objectives: We aimed to evaluate the efficacy and safety of ranolazine in a larger and more
diverse group of patients with angina than previously studied. Background: Ranolazine is an …

BACKGROUND: Ranolazine is a new antianginal drug that reduces intracellular sodium and
calcium accumulation during ischemia, thus potentially limiting myocardial ischemia. It …

Ranolazine is a piperazine derivative believed to reduce anginal symptoms by preventing
ischemia-mediated sodium and calcium overload in myocardial cells through inhibition of …

Background—Ranolazine has been shown to reduce myocardial ischemia and symptom
severity among selected patients with chronic angina. However, data regarding the effect of …

Background Treatments for patients with myocardial ischemia in the absence of
angiographic obstructive coronary artery disease are limited. In these patients, particularly …

Objectives: This report describes safety and tolerability data from 746 chronic angina
patients treated in the ROLE (Ranolazine Open Label Experience) program. Background …